Robin Carson
Overview
Explore the profile of Robin Carson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
835
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fu W, Bang S, Huang H, Kim K, Li W, An G, et al.
Ann Hematol
. 2024 Sep;
103(11):4835-4836.
PMID: 39311958
No abstract available.
12.
Sonneveld P, Dimopoulos M, Boccadoro M, Quach H, Ho P, Beksac M, et al.
Future Oncol
. 2024 Sep;
20(38):3043-3063.
PMID: 39287147
What Is This Summary About?: This summary describes the first analysis of the PERSEUS study, which looked at adults with multiple myeloma that had never been treated before, also called...
13.
Fu W, Bang S, Huang H, Kim K, Li W, An G, et al.
Ann Hematol
. 2024 Sep;
104(1):515-525.
PMID: 39227450
The superiority and tolerability of daratumumab plus bortezomib/melphalan/prednisone (D-VMP) versus bortezomib/melphalan/prednisone (VMP) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) was previously described in the global phase 3 ALCYONE...
14.
Bhatla T, Hogan L, Teachey D, Bautista F, Moppett J, Velasco Puyo P, et al.
Blood
. 2024 Aug;
144(21):2237-2247.
PMID: 39158071
Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) have poor outcomes compared with newly diagnosed, treatment-naïve patients. The phase 2, open-label DELPHINUS study evaluated daratumumab (16 mg/kg...
15.
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al.
Lancet Oncol
. 2024 Jun;
25(8):1003-1014.
PMID: 38889735
Background: CASSIOPEIA part 1 demonstrated superior depth of response and prolonged progression-free survival with daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) alone...
16.
Sonneveld P, Dimopoulos M, Boccadoro M, Quach H, Ho P, Beksac M, et al.
N Engl J Med
. 2023 Dec;
390(4):301-313.
PMID: 38084760
Background: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the...
17.
Spencer A, Moreau P, Mateos M, Goldschmidt H, Suzuki K, Levin M, et al.
Blood Adv
. 2023 Dec;
8(2):388-398.
PMID: 38048391
High-risk multiple myeloma (MM) is often defined based on cytogenetic abnormalities, but patients who relapse early after initial therapy are considered a functional high-risk group. In the phase 3 CASTOR...
18.
Dimopoulos M, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al.
Lancet Haematol
. 2023 Oct;
10(10):e813-e824.
PMID: 37793772
Background: The primary analysis of the APOLLO trial, done after a median follow-up of 16·9 months, showed that daratumumab plus pomalidomide and dexamethasone significantly improved progression-free survival versus pomalidomide and...
19.
Tervonen T, Duenas A, Collacott H, Lam A, Gries K, Carson R, et al.
Value Health
. 2023 Feb;
26(6):909-917.
PMID: 36738785
Objectives: To examine how disease status and current health state influence treatment preferences of patients with multiple myeloma (MM). Methods: Participants with MM from France, Germany, and the United Kingdom...
20.
Dimopoulos M, Oriol A, Nahi H, San-Miguel J, Bahlis N, Usmani S, et al.
J Clin Oncol
. 2023 Jan;
41(8):1590-1599.
PMID: 36599114
Purpose: With the initial analysis of POLLUX at a median follow-up of 13.5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone...